The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Happy Valentine’s Day: Dinner, Sex and Hepatitis C

Back to News Homepage

Next

Understanding Hepatitis B Serology

Sofosbuvir Meets Goals in Hepatitis C Trials

February 11, 2013

Print this page

Inching closer to finding a successful interferon-free treatment for Hepatitis C, Gilead’s Neutrino and Fission trials posted encouraging results for the drug, sofosbuvir.

Gilead’s two hepatitis C drug trials meet study goals

(Reuters) – Biotechnology company Gilead Sciences on Monday said two trials of its hepatitis C drug, the centerpiece of its oral hepatitis C treatment program, met their goals in two late-stage studies.

The results are expected to be used to support the company’s regulatory filing seeking approval in the United States. Industry analysts say the market for such drugs could reach $25 billion by 2020.

An estimated 4 million Americans have the virus, with 170 million infected worldwide.

Gilead’s hepatitis C drugs program is considered among the most advanced of many companies racing to bring an interferon-free treatment regimen to market. The newer hepatitis C drugs, while doubling the cure rate of prior treatments, must still be taken with interferon, which causes miserable flu-like symptoms that lead many patients to discontinue or put off treatment.

Continue reading this entire article:
http://health.yahoo.net/news/s/nm/gilead-s-two-hepatitis-c-drug-trials-meet-study-goals

16 Comments
Share
Share

Previous

Happy Valentine’s Day: Dinner, Sex and Hepatitis C

Back to News Homepage

Next

Understanding Hepatitis B Serology

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.